Abstract
Leydig cell tumours (LCT) are rare testicular neoplasms that usually follow a benign clinical course. Due to the aggressive, difficult-to-treat nature of metastatic disease arising from a small percentage of LCTs, it is imperative to understand and recognize how to identify those tumours which exhibit features that predict malignant behaviour in order to guide initial surgical and oncological management. By using the well-described high-risk histopathological features of Leydig cell tumours as guidance, the management of LCTs has evolved to commonly include testis-sparing surgery (TSS), in patients who historically would have undergone a complete orchidectomy. Thus, assessment of the clinicopathological features of Leydig cell tumours allows for optimal management of this rare disease, whilst modern technologies and surgical techniques have altered the potential treatment landscape. This does not replace the need for the urologist and medical oncologist to remain vigilant in the risk-stratification of patients presenting with these rare testicular sex cord stromal tumours. We present three cases of patients diagnosed with Leydig cell tumours in a single institution in Dublin, Ireland, between 2016 and 2020 and discuss how the clinicopathological features dictate the management and subsequent follow-up for patients presenting with these rare tumours.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.